Evidence map›Paper›PMID 41857312›Full record

ReviewHeart failure reviews2026

Diagnostics in cardio-oncology: a focus on anthracyclines.

Ashot Avagimyan, Nana Pogosova, Daniela Cardinale, Federica Fogacci, Zinaida Djndoyan, Lusine Mkrtchyan, Aysa Rezabakhsh, Arrigo Cicero, Andrea Faggiano, Elisa Gherbesi and 19 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Ashot AvagimyanYerevan State Medical University after M. Heratsi, Yerevan, Armenia. ashot.avagimyan@meduni.am.
Nana PogosovaNational Medical Research Centre of Cardiology after Acad. E. I. Chazov, Moscow, Russia.
Daniela CardinaleCardio-oncology Unit, European Institute of Oncology, I.R.C.C.S, Milan, Italy.
Federica FogacciArterial Hypertension and Cardiovascular Risk Research Centre, Alma Mater Studiourum Università di Bologna, Bologna, Italy.
Zinaida DjndoyanYerevan State Medical University after M. Heratsi, Yerevan, Armenia.
Lusine MkrtchyanYerevan State Medical University after M. Heratsi, Yerevan, Armenia.
Aysa RezabakhshPatient Safety Research Centre, Urmia University of Medical Sciences, Urmia, Iran.
Arrigo CiceroArterial Hypertension and Cardiovascular Risk Research Centre, Alma Mater Studiourum Università di Bologna, Bologna, Italy.
Andrea FaggianoDepartment of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
Elisa GherbesiDepartment of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
Stefano CarugoDepartment of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
Marzieh TaheriIsfahan Cardiovascular Research Centre, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Marco BernardiDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Luigi SpadaforaDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Lorenzo Lo SassoUniversity of Sacred Heart, Rome, Italy.
Francesco PeroneCardiac Rehabilitation Unit, Rehabilitation Clinic "Villa delle Magnolie", Castel Morrone, Caserta, Italy.
Davood ShafieHeart Failure Research Centre, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Manfredi RizzoCardiometabolic Department, University of Palermo, Palermo, Italy.
Azin AlizadehaslCardio-Oncology Department & Research Center, Rajaie Cardiovascular Medical & Research Center, Iran University of Medical Sciences, Tehran, Iran.
Rohit MoudgilCardio-oncology Department, Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, USA.
Pierre SabouretCardiology Department, Heart Institute, Pitié-Salpétrière Hospital, Sorbonne University, Paris, France.
Aaron L SverdlovNewcastle Centre of Excellence in Cardio-Oncology, Hunter Medical Research Institute, Calvary Mater Newcastle, The University of Newcastle, Newcastle, NSW, Australia.
Francesco PrattichizzoIRCCS MultiMedica, Milan, Italy.
Antonio CerielloIRCCS MultiMedica, Milan, Italy.
Giuseppe Biondi-ZoccaiDepartment of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Rosalinda MadonnaCardiology Department, University of Pisa, Pisa, Italy.
Raffaele De CaterinaCardiology Department, University of Pisa, Pisa, Italy.
Riccardo AsteggianoSchool of Medicine, University of Insubria, Varese, Italy.
Nizal SarrafzadeganIsfahan Cardiovascular Research Centre, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases and cancer are the primary causes of morbidity and mortality globally and often occur together. The emergence of cardio-oncology as an independent interdisciplinary field of medicine emphasizes the need for enhanced approaches to diagnose cardiovascular complications in patients with cancer. Although anthracyclines, especially doxorubicin (DOX), are effective against many malignancies, their dose-dependent cardiotoxicity necessitates careful cardiovascular monitoring. Cardiovascular imaging plays a key role in the noninvasive assessment of doxorubicin-associated cardiovascular changes complemented by biomarkers and the evaluation of clinical status. Evidence-based selection and interpretation of images can facilitate early detection of cardiovascular damage, potentially affecting therapeutic interventions and enhancing outcomes following cancer treatment. Advances in innovative diagnostic technologies are crucial for improving the early diagnosis, risk assessment, and monitoring of cardiovascular complications in doxorubicin-treated cancer patients. Further research in this area will refine the patient management strategies at the intersection of cardiology and oncology. This article aims to provide an overview of the diagnostic considerations in cardio-oncology, especially DOX-induced cardiovascular toxicity.

Indexed as

AnthracyclinesAntibiotics, AntineoplasticCardiovascular DiseasesNeoplasmsCardio-OncologyCardiotoxicityHumansRisk AssessmentAnthracyclinesAntibiotics, AntineoplasticCardio-oncologyCardiotoxicityCHODiagnosticsECGMRI

Identifiers

PMID41857312

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.